Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Stopped early · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

This study was planned to determine if neoadjuvant capmatinib could improve the major pathological response (MPR) in patients with Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) lung cancers with Mesenchymal Epithelial Transition (MET) exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation. Treatment was to be continued with capmatinib in the adjuvant setting to evaluate the potential clinical benefit of extended therapy. The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.

Key facts

Study ID

NCT04926831

Run by

Novartis Pharmaceuticals

People needed

4

Starts

2022-08-10

Expected to finish

2024-03-13

Last updated by the study team

2025-10-16

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA Oncology Hematology . — La Jolla, California, United States
• UCLA Oncology Hematology — La Jolla, California, United States
• University of California Davis Cancer Center . — Sacramento, California, United States
• University of California Davis Cancer Center — Sacramento, California, United States
• Fairfax Northern Virginia Hem Onc . — Fairfax, Virginia, United States
• Fairfax Northern Virginia Hem Onc — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.